Caricamento...
Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
BACKGROUND: In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) trial, tolvaptan significantly reduced expansion of kidney volume and loss of kidney function. OBJECTIVE: To determine how benefits observed in the TEMPO trial migh...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3981098/ https://ncbi.nlm.nih.gov/pubmed/24042366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/0003-4819-159-6-201309170-00004 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|